376 related articles for article (PubMed ID: 31933243)
1. The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 10 Years After Approval.
Martín-Merino E; Llorente-García A; Castillo Cano B; Montero Corominas D; Huerta-Álvarez C
Pharmaceut Med; 2019 Dec; 33(6):519-530. PubMed ID: 31933243
[TBL] [Abstract][Full Text] [Related]
2. RETRACTED ARTICLE: The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 6 Years After Approval.
Martín-Merino E; Llorente-García A; Montero Corominas D; Huerta-Álvarez C
Pharmaceut Med; 2019 Apr; 33(2):135-144. PubMed ID: 31933248
[TBL] [Abstract][Full Text] [Related]
3. The recording of human papillomavirus (HPV) vaccination in BIFAP primary care database: A validation study.
Martín-Merino E; Llorente-García A; Montero-Corominas D; Huerta C
Pharmacoepidemiol Drug Saf; 2019 Feb; 28(2):201-208. PubMed ID: 30488510
[TBL] [Abstract][Full Text] [Related]
4. Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges.
Msyamboza KP; Mwagomba BM; Valle M; Chiumia H; Phiri T
BMC Public Health; 2017 Jun; 17(1):599. PubMed ID: 28651574
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain.
Navarro-Illana E; López-Lacort M; Navarro-Illana P; Vilata JJ; Diez-Domingo J
Vaccine; 2017 Jun; 35(25):3342-3346. PubMed ID: 28499554
[TBL] [Abstract][Full Text] [Related]
6. Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis.
Setiawan D; Andrijono ; Hadinegoro SR; Meyta H; Sitohang RV; Tandy G; Perwitasari DA; Postma MJ
PLoS One; 2020; 15(3):e0230359. PubMed ID: 32203527
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2million young girls in France.
Miranda S; Chaignot C; Collin C; Dray-Spira R; Weill A; Zureik M
Vaccine; 2017 Aug; 35(36):4761-4768. PubMed ID: 28750853
[TBL] [Abstract][Full Text] [Related]
8. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084
[TBL] [Abstract][Full Text] [Related]
9. Age impact on human papillomavirus vaccination in France in 2014: A study from the National Health Insurance Database.
Héquet D; Pouget N; Estevez JP; Robain M; Rouzier R
Bull Cancer; 2015 Nov; 102(11):892-7. PubMed ID: 26526386
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study.
Silverberg MJ; Leyden WA; Lam JO; Gregorich SE; Huchko MJ; Kulasingam S; Kuppermann M; Smith-McCune KK; Sawaya GF
Lancet Child Adolesc Health; 2018 Oct; 2(10):707-714. PubMed ID: 30236379
[TBL] [Abstract][Full Text] [Related]
11. Acceptability of two- versus three-dose human papillomavirus vaccination schedule among providers and mothers of adolescent girls: a mixed-methods study in five countries.
Islam JY; Hoyt AM; Ramos S; Morgan K; Kim CJ; de Sanjose S; Butera N; Senkomago V; Richter KL; McDonald MA; Vielot NA; Smith JS
Cancer Causes Control; 2018 Nov; 29(11):1115-1130. PubMed ID: 30284670
[TBL] [Abstract][Full Text] [Related]
12. [The 2-dose schedule of HPV vaccines in young adolescents].
Sehnal B; Neumannová N; Driák D; Halaška M; Kotoulová M; Sláma J
Ceska Gynekol; 2015 Jan; 80(1):50-6. PubMed ID: 25723080
[TBL] [Abstract][Full Text] [Related]
13. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study.
Basu P; Malvi SG; Joshi S; Bhatla N; Muwonge R; Lucas E; Verma Y; Esmy PO; Poli URR; Shah A; Zomawia E; Pimple S; Jayant K; Hingmire S; Chiwate A; Divate U; Vashist S; Mishra G; Jadhav R; Siddiqi M; Sankaran S; Prabhu PR; Kannan TPRA; Varghese R; Shastri SS; Anantharaman D; Gheit T; Tommasino M; Sauvaget C; Pillai MR; Sankaranarayanan R
Lancet Oncol; 2021 Nov; 22(11):1518-1529. PubMed ID: 34634254
[TBL] [Abstract][Full Text] [Related]
14. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.
Drolet M; Bénard É; Boily MC; Ali H; Baandrup L; Bauer H; Beddows S; Brisson J; Brotherton JM; Cummings T; Donovan B; Fairley CK; Flagg EW; Johnson AM; Kahn JA; Kavanagh K; Kjaer SK; Kliewer EV; Lemieux-Mellouki P; Markowitz L; Mboup A; Mesher D; Niccolai L; Oliphant J; Pollock KG; Soldan K; Sonnenberg P; Tabrizi SN; Tanton C; Brisson M
Lancet Infect Dis; 2015 May; 15(5):565-80. PubMed ID: 25744474
[TBL] [Abstract][Full Text] [Related]
15. Uptake of three doses of HPV vaccine by primary school girls in Eldoret, Kenya; a prospective cohort study in a malaria endemic setting.
Mabeya H; Menon S; Weyers S; Naanyu V; Mwaliko E; Kirop E; Orango O; Vermandere H; Vanden Broeck D
BMC Cancer; 2018 May; 18(1):557. PubMed ID: 29751793
[TBL] [Abstract][Full Text] [Related]
16. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
[TBL] [Abstract][Full Text] [Related]
17. The association of adverse events with bivalent human papilloma virus vaccination: A nationwide register-based cohort study in Finland.
Skufca J; Ollgren J; Artama M; Ruokokoski E; Nohynek H; Palmu AA
Vaccine; 2018 Sep; 36(39):5926-5933. PubMed ID: 30115524
[TBL] [Abstract][Full Text] [Related]
18. Parental perspective on human papillomavirus (HPV) vaccination in Serbia: Knowledge, attitudes and practice.
Marić G; Birčanin Đ; Kisić V; Dotlić J; Zarić M; Kisić-Tepavčević D; Gazibara T
Sex Reprod Healthc; 2018 Jun; 16():192-198. PubMed ID: 29804766
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs.
Markowitz LE; Drolet M; Perez N; Jit M; Brisson M
Vaccine; 2018 Aug; 36(32 Pt A):4806-4815. PubMed ID: 29802000
[TBL] [Abstract][Full Text] [Related]
20. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.
Regan DG; Philp DJ; Hocking JS; Law MG
Sex Health; 2007 Sep; 4(3):147-63. PubMed ID: 17931528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]